Announcements Trials
Browse Landscape

Phase

Phase 2 29Phase 3 6Phase NA 5Phase 4 5Phase EARLY_PHASE1 4Phase 1/2 3Phase 2/3 2Phase 1 2

Status

Completed 2Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1CNS 1

Conditions

Ototoxicity 1Hemangioma, Cavernous, Central Nervous System 1Advanced Renal Cell Carcinoma (RCC) 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Atorvastatin × Clear all
NCT07630363 2026-06-05

PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2 Not yet recruiting
40 enrolled
Genitourinary

Advanced Renal Cell Carcinoma (RCC)

NCT06553157 2026-01-20

Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy

Minia University

Phase 1/2 Completed
56 enrolled

Ototoxicity

NCT02603328 2025-08-22

AT CASH EPOC

University of Chicago

Phase 1/2 Completed
80 enrolled 19 charts
CNS

Hemangioma, Cavernous, Central Nervous System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡